AP-010

LBCL, 75 plus, rural, Medicare, 76 to 150 miles

Allo-HCT · Phase 2, Candidacy Evaluation · 24 days in stage · 11 barriers, 3 blocking

Watch24 days in work-up to candidacy decision, approaching the 30-day target

Follow one barrier

Diagnosis & Referral

From diagnosis to first contact with an accredited center.

Any order, all required

Start ahead · work beginning here for later phases

Confirm the center’s caregiver requirement and any flexibility · Caregiver & psychosocial clearance · for phase 2
Start caregiver planning now; explore paid-caregiver and respite options · Caregiver & psychosocial clearance · for phase 2
Connect family to caregiver stipend / paid-leave resources and advocacy · Caregiver & psychosocial clearance · for phase 2
Plan bridging early with a standardized protocol; avoid bendamustine before apheresis · Manufacturing / collection & vein-to-vein risk · for phase 4
Enroll in manufacturer assistance / copay programs · Financial toxicity / out-of-pocket burden · for phase 2
Arrange non-emergency medical transport (NEMT) and confirm coverage · Transportation barrier · for phase 2

The work-up that determines whether the center will proceed. Most tests run in parallel and all feed the selection decision.

Any order, all required

Start ahead · work beginning here for later phases

Ask about early leukapheresis + cryopreservation to protect T-cell fitness · Manufacturing / collection & vein-to-vein risk · for phase 4

Securing payer approval and financial clearance for the specific therapy.

Any order, all required

Obtaining the cells and getting the patient ready. This is where CAR-T and allogeneic transplant diverge.

Allo-HCT track

Shared preparation — in parallel with collection

Any order, all required

Conditioning, infusion, and the acute monitoring window.

Monitoring, transition back home, and long-term survivorship.